


COST ANALYSIS OF SELF-INJECTABLE ANTI-TNF IN ALMERIA (SPAIN)

Acosta-Robles P(*), Gimeno-Jordá MJ (*), Tarín-Remohí MJ (**), Sánchez-Arcos A (**), Fayet-Pérez A(*), Pinto-Nieto C (*).

(*) Pharmacy Department Hospital de Poniente. El Ejido (Almería). Spain

(**) Pharmacy Department Complejo Hospitalario Torrecárdenas. (Almería). Spain



BACKGROUND AND OBJETIVES

Etanercept (ETA) and Adalimumab (ADA) are some of the biologic agents available for treating severe psoriasis and different inflammatory diseases in patients who have an inadequate response to standard treatment.

The *objective* of this study is to analyze and evaluate current costs for the regional health system of the treatment of the following inflammatory diseases: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) with self injectable main anti-TNFs drugs in Almería public hospitals (Spain).


MATERIAL AND METHODS

Retrospective multicenter study including all patients treated with ETA or ADA (n= 300 patients) during the period January-December 2010 in all Almería public hospitals.

RESULTS


In the light of these results and taking into account that both drugs have similar efficacy, ETA appears to be the most favourable option in the treatment of RA and AS.

Average Annual Cost per Patient




■ Adalimumab	9.931,60 €	10.162,50 €	6.577,80 €
■ Etanercept	7.363,50 €	8.146,20 €	8.585,90 €

% Patients per Pathologies



% Patients/ Pathology/ Therapy



CONCLUSIONS

For higher prevalence and incidence pathologies, etanercept is the most economical option, therefore it is proposed as first-line treatment, leaving adalimumab as a second line in case of lack of response. It is necessary to perform longer-term studies and including the rest of anti TNF drugs currently used to position each one in its maximum efficiency indication.

Poster number OHP015